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Glioblastoma (GBM), a form of glioma, is an aggressive form of human cancer with a 
median survival time of 14.6 months with after diagnosis.  It is the most common and 
most aggressive form of brain cancer due to its invasive and angiogenic nature.  Gliomas 
develop their vascularized networks through the process of angiogenesis, the 
development of blood vessels.  In tumor development, angiogenesis is marked by a few 
hallmark characteristics: degradation of the basement membrane, recruitment of 
endothelial cells, and tube network formation among recently recruited endothelial cells 
to finalize the formation of a new blood vessel.  Angiogenesis increases vascular 
permeability of blood vessels, which can ultimately progress from edema, to neurological 
deficits, to death.  Anti-angiogenic therapies have been favored for reducing symptoms 
related with edema.  Imipramine Blue (IB) is a novel compound used to treat gliomas.   
In vivo, it decreases invasion and prolongs survival.  It is believed that IB’s ability to stop 
tumor cells from invading into neighboring areas also inhibits angiogenesis.  If the tumor 
cells cannot move to create more blood vessels, then angiogenesis might also be 
inhibited.   Additionally, it is believed that IB might stop the recruitment of endothelial 
cells, similar to how IB stops tumor cell invasion.  This study investigated Imipramine 
Blue’s possible anti-angiogenic effects.   
In vitro, IB did not affect MMP-2 and MMP-9 activity in U87 and RT2A glioma cell 
lines (ANOVA).  IB did not affect HUVEC invasion (p=0.08, two-pair, student’s t-test, 
α=0.05).  In vivo, animals were treated with IB liposomes or plain liposomes, and 
vascular permeability was assessed using kinetic image analysis from MRI with the aid 





studies that want to investigate different variables from the same brain.  No significant 
differences in endothelial transfer coefficients (KPS) were observed between treatment 
groups (two-sample student’s t-test, p = 0.3488), suggesting IB does not affect vascular 








1.1. GLIOMAS AND THEIR CHARACTERISTICS 
Glioblastoma (GBM), a form of glioma, is an aggressive form of human cancer with 
a median survival time of 14.6 months with treatment (surgery, radiation, and 
chemotherapy) after diagnosis.1  It is the most common and most aggressive form of 
brain cancer.2 GBM's tumor originally arises from the glial cells of the brain. Like any 
form of cancer, GBM has the potential of invading neighboring tissue (invasion), but 
what separates gliomas from other forms of cancer is the primary organ in which it 
originates.  The brain is the central controlling unit of the body.  Tumor growth can create 
intracranial pressure, forcing the tissue to shift, resulting in eventually death due to stroke 
(disturbance of blood flow in the brain) or cerebral edema (excess accumulation of water 
in the brain).3    
1.2. ANGIOGENESIS IN GLIOMAS 
Gliomas develop their vascularized networks through the process of angiogenesis, the 
development of blood vessels.  In tumor development, angiogenesis is marked by a few 
hallmark characteristics.  Growth factors released from tumor cells activate receptors on 
nearby pre-existing blood vessels, causing the release of enzymes called matrix 
metalloproteases (MMPs).4  Matrix metalloproteases degrade the basement membrane or 
inner lining of the blood vessel to make room for the development of new blood vessels.  
In gliomas, MMP-2 and MMP-9 are significantly overexpressed.5   Simultaneously, the 
blood vessel’s pre-existing endothelial cells release chemical messengers to induce 
endothelial cell recruitment towards the site of angiogenesis (known as endothelial cell 
chemotaxis).  Blood vessels are mainly composed of endothelial cells.  They are the 





site of degraded basement membrane.   Next, the newly recruited endothelial cells will 
form tube-like structures with neighboring endothelial cells.  These networks will 
facilitate the development of blood vessel formation.4   
 
Throughout the process of angiogenesis, growth factors are overexpressed.  An 
imbalance of these growth factors causes the newly formed vessels to be disorganized 
and underdeveloped6.  The endothelial cells which make up the lining of the vessel have 
large gap junctions as a result of the imbalance in growth factors7.  The creation of large 
gap junctions increases the permeability of the blood vessel, which causes fluid 
accumulation in tumors. Tumor permeability has been observed to increase up to 20 fold 
compared to healthy patients.8  The blood-brain barrier is the separation between blood 
and cerebrospinal fluid.  It is highly selective of deciding what can reach brain tissue.  
Gliomas disrupt the structure of the blood-brain barrier, allowing for unwanted fluid to 
accumulate.  Fluid accumulation (edema) can increase interstitial fluid pressure and 
neurological deficits.  Furthermore, interstitial fluid pressure has been shown to decrease 
drug delivery.  Although edema can be treated with steroid therapy, it is not favored due 
to the adverse side effects associated with steroids.  Therefore, development of anti-
angiogenic therapies is favored to reduce symptoms of edema and increase drug 
delivery.8     
 
1.3. TREATMENTS FOR GLIOMAS 
The low chances of surviving GBM are associated with the invasive and highly 
vascularized nature of the tumor.  Unfortunately, current treatments are mainly focused 





rather than finding a cure.3  Treatments include surgery, radiotherapy, and chemotherapy.  
MRI (magnetic resonance imaging) and CT (computed tomography) can be used for 
initial detection of a tumor prior to surgery, but a biopsy analysis, extraction and analysis 
of the tumor cells, is the only way of determining the grade or malignancy of the tumor.3  
Removal of the tumor, or resection surgery is usually conducted to decrease symptoms 
and to obtain samples for diagnosis.3  Unlike other forms of cancer, tumors in the brain 
are difficult to remove without neural complications arising.  Removal of a tumor located 
in areas necessary for cognitive function could result in the inability of the patient to 
retain information or think as well as he or she could previously.  Even after personalized 
therapy, tumors recur with a median survival of 25 weeks.1 For this reason, it is essential 
to find more effective means of prolonging survival by targeting GBM's invasiveness and 
vasculature.  The Bellamkonda Lab of Georgia Tech uses nanotherapeutics to target these 
characteristics.   
 
2. LITERATURE REVIEW 
2.1. NANOTHERAPEUTICS 
Nanotechnology has been a thriving focal point of today's innovations because it can 
perform tasks on a molecular scale and possess a widespread of applications.  
Consequently, there has been a spike in funding for research in this field for cancer 
therapy because it has the potential of analyzing and stopping cancer on the molecular 
scale.  For instance, the National Cancer Institute committed $144.3 million for their 
cancer-nanotherapy sector from 2005 to 2010.7  To be considered nanotechnology, an 





nanoparticles are: nanoshells, carbon nanotubes, dendrimers, quantum dots, 
superparamagnetic nanoparticles, and liposomes.7  They can be used for drug delivery, 
gene therapy, or imaging.  Each type of nanoparticle takes advantage of the same general 
mechanisms of targeting cancer cells--recognizing and finding the tumor and delivering a 
load to the tumor cells (anti-cancer drugs, genes, or contrast-enhancing agents).7  
 
2.2. LIPOSOMES 
Of these nanoparticles, liposomes comprise a considerable amount of nanotechnology 
research in biomedicine.  Liposomes are vesicles, like cells, but without organelles inside 
their aqueous center (Figure 1).9 Liposomes with membranes composed of naturally 
occurring phospholipids and cholesterol are not used for drug delivery because they are 
easily detected, marked as a "foreigner", and removed by the reticuloendothelial system 
(RES).10  Therefore the membranes are conjugated with molecules to inhibit the liposome 
from being marked as a "foreigner" and cleared from the blood.  Polyethylene glycol 
(PEG) is a commonly used conjugate because it spatially blocks the liposome from being 
marked for plasma clearance (or removed from the body).10  Studies have shown that 
PEG-conjugated liposomes yield a systemic plasma clearance 200-fold less than the non-
PEG conjugated liposomes.10  PEG has become a standard conjugate because it allows 
liposomes to circulate the body significantly longer than non-conjugated liposomes.  






Figure 1: Liposome Schematic: Vesicle of about 100nm with a phospholipid bilayer and aqueous core.11 
 
The size of the liposome also aids in avoiding RES clearance.   RES clearance of 
liposomes occurs in the sinusoid of the spleen and the liver.  Their filtration vessels range 
from 150 to 200 nm in diameter. Particles larger than the vessel diameter are retained in 
the organs and are isolated from the rest of the body.  Liposomes less than 150 nm can be 
passed through the vessels and returned to the blood stream.  As a result, combinations of 
lipids, conjugates, cholesterol, and drugs have been tailored to find favorable 
formulations with higher circulation times. 
Liposomes enter tumors via the enhanced permeability and retention effect 
(EPR).6  A growing tumor needs nutrients in order to survive, typically resulting in the 
rerouting and generation of new blood vessels (angiogenesis).6, 12  This allows particles 
up to 400nm in diameter, like liposomes, to passively accumulate in the tumor (Figure 
2).7  In contrast, non-tumor sites do not experience passive liposome accumulation 





Recent studies have shown that liposomes can be loaded with chemotherapeutic drugs to 
increase circulation time, increase concentration delivered to the point of interest, and 
decrease toxicity effects to vital organs.13  For example, doxorubicin, a common 
chemotherapeutic, has been delivered in clinical trials to gliomas with success at 
passively targeting the tumor.14  In contrast, no anti-invasive drugs are currently on the 
market.  Although, there is a necessity for them, since invasion is an underlying 




Figure 2: Nanoparticles delivered to tumor tissue via EPR Effect.  The endothelial cells lining the blood 
vessel are more spaced out allowing nanoparticles of up to 400 nm in diameter to pass through and 




2.3. LIPOSOMAL CONTRAST AGENTS 
T1-based magnetic resonance (MR) contrast agents have enabled more applications 
of magnetic resonance imaging (MRI) in tumor detection, tumor characterization, and 
vascular imaging.    Gadolinium (Gd) chelates are ideal for imaging because they 
decrease T1 relaxation times.15  However, bolus injection timing is important  due to 
gadolinium’s small window of efficacy and three hour half-life.16  For in vivo small 





Ghaghada et al. synthesized gadolinium liposomes: core encapsulated, surface 
conjugated, and dual (core encapsulated and surface conjugated) formulations. Three 
days after tail vein injections of the different formulations, animals were imaged.  Rats 
which were administered the dual gadolinium formulation exhibited significantly higher 
nanoparticle-based T1 relaxivity, signal to noise ratio, and contrast to noise ratio, 
compared to rats with contrast-enhanced and surface conjugated gadolinium liposomes.15   
 
2.4. IMIPRAMINE BLUE 
In the Bellamkonda Lab at Georgia Tech, liposomes are being developed to stop 
invasion, clearly define the tumor for resection, and treat residual tumor cells left over 
from resectioning. Past projects have involved analyzing the effects of the novel drug, 
Imipramine Blue (IB), on a rat model of invasive glioma in vivo. Imipramine Blue is a 
drug developed by the Arbiser Lab of Emory University.  It has poor solubility and 
circulation time in the bloodstream, so encapsulating the drug in a liposome is favorable 
to increase circulation in the body. This drug appears to limit invasion of tumor into 
healthy brain tissue but does not cause cytotoxic effects (i.e. induced cell death) in 
healthy tissue (Figure 3).  
It is believed that IB’s ability to stop tumor cells from invading into neighboring areas 
could also inhibit angiogenesis.  If the tumor cells cannot move to create more blood 
vessels, then angiogenesis might also be inhibited.   Additionally, it is believed that IB 
might stop the recruitment of endothelial cells, similar to how IB stops tumor cell 
invasion.  Typically, rats inoculated with the untreated 3RT1-RT2A tumor model show 
signs of morbidity by day 12.  Survival studies using the 3RT1-RT2A tumor model have 





liposomal doxorubicin (a chemotherapeutic agent) have delayed signs of morbidity from 
12 days to 8 months, which is significantly greater than rats treated only with Imipramine 
Blue or doxorubicin.  It is believed that Imipramine Blue possesses anti-angiogenic 
effects on vascular permeability, accounting for the prolongation of survival in rats 
treated with liposomal IB and doxorubicin 
 
Figure 3: Effects of Imipramine Blue in Rat Glioma (3RT1-RT2A) Model.   Tumors were injected 
2mm anterior and lateral to lambda and 3 mm below the dura.  Animals were administered tail-vein 
injections (saline or liposomal IB) on Day 4 and 7 (after tumor inoculation) and perfused on Day 11.  
Brains were sectioned coronally and stained with DAPI to highlight nuclei.  The treated tumor appears 






3. MATERIALS AND METHODS 
3.1. MATERIALS 
3.1.1. CELL CULTURE MATERIALS 
96-well plates (black-bottom), tissue-culture treated 96-well plates (clear) and 
T75 flasks were purchased from VWR (West Chester, PA).  Trypsin-EDTA (0.05% 
trypsin, 0.53 mM EDTA) in Hanks’ balanced salt solution was purchased from 
Mediatech (Manassas, VA).  5x  basement membrane extract (BME) and 10x coating 
solution were purchased from Trevigen (Gaithersburg, MD).  Dye-quenched (DQ) 
collagen (IV) and 4’,6-Diamidino-2-phenylindole (DAPI) were purchased from 
Invitrogen.  Transwells with 8 micron pore size were purchased from Millipore. 
Paraformaldehyde was purchased from Sigma (St. Louis, MO).   
3.1.2. CELL LINES 
U87MG human glioma cell line was purchased from American Type Culture 
Collection, (Manassas, VA) and grown in T-75 flasks in growth medium.  U87MG 
growth medium consisted of Dulbecco’s Modified Eagle’s Medium (DMEM)  
supplemented with 10% Fetal Bovine Serum (FBS), 1% Penicillin/Streptomycin 
(P/S), 1% Non-Essential Amino Acids , and 1% L-glutamine (L-glut) (Gibco, 
Carlsbad, CA).  RT2A and 3RT1-RT2A (eGFP-expressing RT2A) rat glioma cell 
lines were obtained from Helen Fillmore in the Department of Neurosurgery from the 
Virginia Commonwealth University.  RT2A was grown in T-75 flasks in U87MG 
growth medium previously mentioned.  3RT1-RT2A growth medium included the 
same formulation for U87MG and RT2A growth medium with the addition of 





U87MG, RT2A, and 3RT1-RT2A consisted of DMEM supplemented with 1% 
Penicillin/Streptomycin, 1% Non-Essential Amino Acids , and 1% L-glutamine. 
 
Human Umbilical Vein Endothelial Cells (HUVEC) were a generous gift from 
Larry V. McIntyre and cultured in T-75 flasks treated with 0.2% gelatin (Sigma, St. 
Louis, MO) in Medium 199 (M199, Mediatech, Manassas, VA) supplemented with 
16.28% Fetal Bovine Serum, 0.98% Penicillin/Streptomycin,  0.98% L-glutamine, 
0.2% heparin (1000 USP units ml−1, Baxter Healthcare, Deerfield, IL), and 0.16% 
endothelial mitogen (25 mg reconstituted in 2 ml M199, Biomedical Technologies, 
Stoughton, MA).  Low serum media consisted of M199 supplemented with 0.05% 
Fetal Bovine Serum, 0.98% Penicillin/Streptomycin, 0.98% L-glutamine, 0.2% 
heparin, and 0.16% endothelial mitogen. 
3.1.3. IMIPRAMINE BLUE AND LIPOSOME MATERIALS 
Imipramine Blue was obtained from the Arbiser Laboratory of Emory University.  
Stock solutions for in vitro experiments diluted Imipramine Blue in ethanol.    
Distearoyl (sn-glycero) phosphotidylcholine (DSPC), poly (ethylene glycol) 2000-
distearoyl-phosphatidyl ethanoloamine (DSPE-PEG 2000), 1,2-dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC), and Gd-DTPA bis(stearylamide) (Gd-DTPA-
BSA)  were purchased from Avanti (Alabaster, AL).  Cholesterol was purchased from 
Sigma (St. Louis, MO).  Gadolinium DTPA (Omniscan) and sepharose were 
purchased from GE Healthcare.  Nuclepore extrusion filters of 0.4 µm 0.2 μm were 
purchased from Millipore.  A 10 ml Lipex Thermoline extruder was purchased from 





3.1.4. ANIMAL STUDY MATERIALS 
Fisher 344 rats (n=6) were purchased from Harlan (Indianapolis, IN).    A stereotaxic 
frame was purchased from Kopf Instruments (Tujunga, CA).  Marcaine (0.5%) was 
purchased from Abbott Laboratories (Abbott Park, IL).  Isoflurane was purchased from 
Baxter Healthcare (Deerfield, IL).  A 10 μl Hamilton syringe was purchased from 
Hamilton. Sutures (4-0) were purchased from Ethicon. Buprenorphine (0.05 mg/kg) was 
purchased from (Reckitt Benckiser).   Nalgene syringe filters (0.2 μm) were purchased 
from Thermo Scientific (Rochester, NY). Ketamine (100 mg/ml) was purchased from 
Fort Dodge Laboratories (Madison, NJ).  Xylazine (100 mg/ml) was purchased from The 
Butler company (Dublin, OH). Acetylpromazine (10 mg/ml) was obtained from 
Boehringer Ingelheim (Ingelheim, Germany).  Optimal Cutting Temperature (OTC) 
Compound was purchased from VWR (Batavia, IL).   
3.2. IN VITRO ANGIOGENESIS ASSAYS 
3.2.1. MATRIX METALLOPROTEINASES ASSAY 
U87MG human glioma cell line and RT2A rat glioma cell lines were cultured to 
confluence in growth medium.  5x BME was diluted to 1x in DMEM.  Dye-quenched 
collagen (IV) was then diluted in the 1x BME solution to a final concentration of 1mg/ml. 
Dye-quenched collagen contains an excessive amount of fluorescein (fluorescent dye) 
attached to its structure.18  The excessive amount of fluorescein decreases the spacing 
among neighboring fluorescein, resulting in almost no fluorescent signal emitted.  When 
dye-quenched collagen is cleaved into fragments, a separation between the fluorescein is 
created, allowing for fluorescent emission.  Emission of fluorescent signal indicates 





collagen IV and basement membrane extract simulate the basement membrane of the 
blood vessel.   
A 96-well plate was coated with the dye-quenched collagen and BME solution 
and incubated at 37°C for 30 minutes.  Wells were coated with glioma cell lines (50,000 
cells/well, resuspended in 50 μl basal media) and treated with varying concentrations of 
Imipramine Blue (0 to 100 μM).  Plates were then incubated for 16-24 hours and FITC 
imaged under 10x magnification.  FITC intensity levels indicating MMP activity were 
observed using ImageJ.  Average FITC intensity levels were recorded, normalized to the 
control (0μM), and compared using a one-way ANOVA to detect significant differences.  
If the one-way ANOVA detected a significant difference, a Tukey comparison was used 
to determine which pairs were significantly different 
 
3.2.2. ENDOTHELIAL CELL INVASION ASSAY 
A 10x coating solution was diluted to 1x in sterile water.  A 5x BME solution was 
then diluted to 1x using the diluted 10x coating solution previously mentioned, creating 
the final BME coating solution.  Transwells were placed in 24-well plates, coated with 
the BME coating solution, incubated at 37°C for 16-24 hours, and aspirated and washed 
with PBS.  Transwells were then coated with cells (50,000 cells/well) and treated with 
varying concentrations of Imipramine Blue (0, 5μM in low serum HUVEC media) on the 
apical side of the transwell.    Wells were filled with basal media to the level of media in 
the transwell, preventing a pressure gradient.  Plates were incubated for 24 hours.  
Transwells were fixed with 4% paraformaldehyde, DAPI stained, and imaged under 20x 





compared to the control using a student’s two sample t-test (2 tail, α=0.05) to observe 
significant differences. 
3.3. IN VIVO VASCULAR PERMEABILITY QUANTIFICATION  
The in vivo vascular permeability study followed the timeline outlined in Table 1.  .   
 
Table 1: Treatment Groups for Vascular Permeability Study 
Day Treatment 
0 Inoculate tumor  
4 Tail vein injections 
Group 1, liposomal IB (n=3) 
Group 2, plain liposomes (n = 3) 
7 Pre contrast images for random members of groups 1 and 2 
Tail vein injections of dual gadolinium liposomes, both groups 
10 MRI both groups 
12 Perfusions 
 
3.3.1. IMIPRAMINE BLUE LIPOSOME FORMULATION 
Liposomes were synthesized by dissolving distearoyl (sn‐glycero) 
phosphotidylcholine (DSPC) , poly (ethylene glycol) 2000‐ distearoyl‐phosphatidyl 
ethanoloamine (DSPE‐PEG2000), cholesterol, and 2 mg/ml Imipramine blue in ethanol.  
A molar ratio, 85:5:10, of DSPC: DSPE-PEG2000: cholesterol was dissolved in 10% 
final volume of ethanol at 70°C and hydrated with phosphate buffered saline (PBS) to 40 
mM lipid molarity.  The liposomes were then extruded five times through a 0.4 μm 
Nuclepore filter and then seven times through a 0.2μm Nuclepore filter using a 10ml 
Lipex Thermoline extruder to standardize the size of the liposomes to under 200 nm.  The 
average diameter of the liposomes was determined using dynamic light scattering, which 
was approximately 160nm.  Next, the remaining free drug was separated from the 





diafiltrated to a smaller volume, approximately to a final IB concentration of 7 mg/ml in 
140 mM lipids.  IB concentration was quantified using a spectrophotometer with an 
excitation and emission of 590 nm and 625 nm.  Prior to tail-vein injections, liposomes 
were filtered through a 0.2 μm pore filter. 
3.3.2. PLAIN LIPOSOME FORMULATION 
Liposomes were synthesized with a molar ratio, 85:5:10, of DSPC: DSPE-
PEG2000: cholesterol, dissolved in 10% final volume of ethanol at 70°C, and hydrated 
with phosphate buffered saline (PBS) to 150 mM lipid molarity.  The liposomes were 
then extruded five times through a 0.4 μm Nuclepore filter and then seven times through 
a 0.2μm Nuclepore filter using a 10ml Lipex Thermoline extruder to standardize the size 
of the liposomes to under 200 nm.  The average diameter of the liposomes was 
determined using dynamic light scattering, which was approximately 160nm.  The 
liposomes were dialyzed against PBS to remove the remaining ethanol.  Prior to tail-vein 
injections, liposomes were filtered through a 0.2 μm pore filter. 
3.3.3. DUAL GADOLINIUM LIPOSOME FORMULATION 
Dual gadolinium liposomes were synthesized in a method similarly described by 
Ghaghada et al.15  Liposomes were synthesized by dissolving DPPC, Gd-DTPA 
bis(stearylamide) (Gd-DTPA-BSA), cholesterol, and DSPE-PEG 2000 with a molar ratio 
of 30:25:40:5 in a chloroform-methanol (1:1 v/v) solution.  The lipid solution was then 
evaporated to dryness using a vacuum and hydrated with a solution of gadodiamide 
(OmniScan®) to a final lipid concentration of 40mM.  The solution was stirred at 60°C 
for 90 minutes.  The liposomes were then extruded five times through a 400 nm 





through a 100 nm Nuclepore membrane.  The final liposome solution was then dialyzed 
against PBS to remove free gadolinium. 
3.3.4. 3RT1-RT2A GLIOMA CELL CULTURE 
The cell line was carried (trypsinized and washed with growth media) until the 
fourth passage, and 200,000 cells were suspended in 10 μl Leibovitz's L-15 Media. 
3.3.5. TUMOR INOCULATION 
Six Fisher 344 adult rats were implanted with tumors by sterile surgical 
techniques approved by the Institutional Animal Care and Use Committee (IACUC) at 
the Georgia Institute of Technology. The animals were anesthetized with 2-3% isoflurane 
and positioned in a stereotactic frame.  The scalp was prepared and anesthetized with 
0.5% marcaine.  A 2-3 cm incision was made with a No. 10 scalpel.  The periosteum was 
removed, and lambda was exposed.  A 2 mm burr hole was drilled, 2 mm anterior and 
lateral from lambda.  This injection point was determined to be common in glioma 
occurrences and yielded the most consistent tumors17. The 200,000 cells suspended in 10 
μl Leibovitz's L-15 Media were slowly injected, 3 mm into the dura, using a Hamilton 
syringe.  After injection, the syringe was slowly removed, and the burr hole was covered 
with bone wax.  Finally, the scalp was sutured closed (Ethicon), and the rat was 
administered an intramuscular injection of buprenorphine (0.05mg/kg) to alleviate pain.  
Rats were monitored daily for signs of morbidity: change in fur color, weight loss, or 
inactivity. 
3.3.6. TAIL VEIN INJECTIONS 
On day 4 after tumor inoculations, the rats were administered tail-vein injections.  





Blue liposomes.  Day 4 was chosen as the first day of injection because it is when 
angiogenesis is first seen in histological analysis.  For the first treatment, groups were 
administered treatments (5mg IB/kg rat).  On day 7, both groups were administered 0.15 
mmol Gd/ kg rat.  
 
3.3.7. MAGNETIC RESONANCE IMAGING 
On day 7 prior to tail vein injections, one animal from each group was MR 
imaged for precontrast images.  Animals were anesthetized by 1-2% Isoflurane, then 
placed in a 7T MRI (Bruker).  A T1-weighted image was taken through the head using 
the following parameters: a range of 50ms - 2.0 s repetition time (TR), 48 ms echo time 
(TE), FOV = 40 mm x 40 mm with a 256 x 256 matrix, slice thickness = 5 mm, number 
of slices = 1, 4 averages per phase encode step requiring a total acquisition time of about 
25 minutes per rat.  Furthermore, a 3x3 cut out of a clear 96-well plate containing varying 
concentrations of dual-gadolinium liposomes were imaged. 
 
3.3.8. IMAGE AND DATA ANALYSIS 
3.3.8.1. KINETIC ANALYSIS 
Vascular Permeability was assessed by determining each tumor’s endothelial 
transfer coefficient (KPS [ml min-1100 cc-1 of tissue]) similarly to a method developed by 
Daldrup et al.19  Concentration of gadolinium in the tumor (CT) is a function of 
gadolinium accumulation in interstitial (CI) and plasma spaces (fpvCp, where fpv is the 
fractional plasma volume of the tumor tissue [mL cc-1 of tissue] and Cp is the 










The rate of interstitial gadolinium accumulation (Eq. 2) is a function of the endothelial 
transfer coefficient (KPS), the concentration of gadolinium in the plasma and the reflux 
from interstitial water back to the plasma, where k is the reflux rate constant.   




The solution to Eq. 2 is shown below in Eq. 3.   
 






3.3.8.2. MRI DATA EXTRACTION 
Pre-contrast images were not used for the kinetic analysis of MR images because 
it was determined that the difference in tumor sizes from day 7 and day 10 would affect 
the amount of gadolinium accumulated at the tumor.  MR images were converted into 
MATLAB colormaps by a program provided by Dr. Johannes Leisen.  The colormaps 
displayed T1 relaxivity and inverse T1 relaxivity (1/T1) values.  T1 and 1/T1 colormap 
scales were adjusted (T1: (0, 4000); 1/T1: (4E-4, 8E-4)). Areas on the 96-well plate T1 
colormap corresponding to varying concentrations of gadolinium were traced, and 





converted to T1 values on the colormap scale, and an exponential regression was created 
relating the amount of gadolinium (mmol) to T1 values. 
 
ImageJ was used for tumor analysis.  Tumors on T1 colormaps were outlined.  
Tumor area and mean tumor RGB values were extracted.  RGB values were converted to 
T1 values using the colormap scale.  Finally, the T1 values were converted to amounts of 
gadolinium (mmol) using the exponential regression.  These values were divided by the 
product of the tumor area and MR image depth (volume of tumor section), converted to 
mmol/cc and recorded as CT(t=72 hours).  
 
No pharmacokinetics studies have been published for the dual gadolinium 
liposome formulation developed by Ghaghada et al., so gadolinium accumulation in the 
plasma was modeled from a stealth liposome model.15, 20  This model is analogous 
because of the similar lipid content.  Stealth liposomes were core encapsulated with 
doxorubicin, and doxorubicin plasma levels were monitored over time20.  Doxorubicin 
plasma concentration modeled a decreasing exponential curve (Figure 4).  This model 
was applied to gadolinium accumulation.  The vehicle of delivery (liposome) is what 
limits the amount of core encapsulated gadolinium which will be released into the 
plasma, so this is an applicable model for Cp(t).  It was assumed that dual-gadolinium 
liposomes would have the same release profile in the plasma concentrations of mg/ml 













































Figure 5: Predicted gadolinium concentration in plasma of rats treated with dual-gadolinium 



































Daldrup et al. used k =0 for albumin-conjugated gadolinium.19  Liposomes have a similar 
clearance rate as albumin, so k was also assumed to be 0 for the dual-gadolinium 
liposomes.  Fractional plasma volume of 0.177 mL cc-1 was taken from control animals 
by a similar study by Gossman et al.21 Rats were inoculated with U87 gliomas and MR 
imaged on day 16 to evaluate an anti-angiogenic therapy using the method described by 
Daldrup et al.19  KPS was then solved using Eq 4.    
 
3.3.9. PERFUSIONS AND BRAIN PROCESSING 
On day 12 the animals were perfused intracardially with PBS.  Prior to perfusion, the 
rats were anesthethized by an intraperitoneal injection of ketamine, xylazine, and 
acetylpromazine (respectively 50, 10, and 1.67 mg/kg).  Extracted brains were fixed in 
4% paraformaldehyde in PBS for 1 hour at 4°C then stored in 4% sucrose (wt-vol % in 
PBS) at 4°C until saturated, embedded in optimal cutting temperature compound (OCT), 
stored at -80°C and cryosectioned coronally into 16 μm slices.   
4. RESULTS 
 
4.1. IN VITRO 
 
4.1.1. MMP ACTIVITY 
 
 
Some significant differences were observed in U87 and RT2A MMP activity 
(Figures 7 and 8).  A significant difference was observed in U87 cells between 0.001 μM 
IB and 50 μM IB treatment groups(p=0.000).  Similarly, significant differences were 
observed in RT2A cells between 1 μM IB and 50 μM IB (p=0.016).  U87 MMP activity 





increased.  As IB treatment increased, RT2A MMP activity increased from 0 μM IB to  
0.1 μM IB and 1 μM IB, peaked, and then decreased from 1 μM IB to 100 μM IB. 
 
A. 
B.  0 μM 
 
































Figure 6: MMP Activity in IB-Treated U87 Cells.  U87 cells were seeded on a basement membrane 
extract which included a dye-quenched collagen IV.  When the collagen IV is cleaved by MMP-2 and 
MMP-9, a green fluoroscein is emitted.  A. shows the treated U87 MMP-2 and MMP-9 activities.  
Asterixes denote the significant differences according to a one-way ANOVA and Tukey-post test (α=0.05).  
Significant differences were observed between treatment groups 0.001 μM IB and 50 μM IB (* p = 0.000),. 















B. 0 μM  
 































Figure 7:  MMP Activity in IB-Treated RT2A cells.  RT2A cells were seeded on a basement membrane 
extract which included a dye-quenched collagen IV.  When the collagen IV is cleaved by MMP-2 and 
MMP-9, a green fluoroscein is emitted.  A. shows the treated RT2A MMP-2 and MMP-9 activities.  
Asterixes denote significant differences according to a one-way ANOVA and Tukey-post test (α=0.05).  
Significant differences were observed between treatment groups 1 μM IB and 50 μM IB (* p = 0.016). B. 






4.1.2. HUVEC INVASION 
 
Treated HUVEC invasion showed a decreasing trend but was not significant (p = 
0.08, Figure 8).    
 
 
Figure 8: Invasion of IB-Treated HUVECs.  HUVECs were seeded and treated  either 0 μM IB or 5 μM 
IB (n=3 per treatment), incubated for 24 hours, 4% paraformaldehyde fixed, DAPI stained, and imaged.  
Invasion through the transwell was quantified and normalized to the control.  Treated HUVEC invasion 





























4.2. IN VIVO VASCULAR PERMEABILITY QUANTIFICATION 
 
No significant differences were observed between treatment groups in terms of 
endothelial transfer coefficients and cross-sectional tumor area (p1=0.3488, p2=0.187).  
MR images are seen in Figure 9, displaying the inverse T1 relaxivities.  Red areas 





Table 2: Endothelial Transfer Coefficients (KPS) and Cross-Sectional Tumor Areas in Plain 
Liposome-Treated and Imipramine Blue Liposome-Treated 3RT1-RT2A Tumors. Units for KPS and 
cross sectional tumor area are mL min-1100 cc-1 of tissue and mm2.  No significant differences were 
observed between treatment groups in terms of endothelial transfer coefficients and cross-sectional tumor 
area (p1=0.3488, p2=0.187). 
Plain Liposomes  Imipramine Blue Liposomes 
ID # KPS 
Cross-
sectional 




1 0.647 0.808 4 13.466 0.058
2 6.927 0.126 5 3.398 0.209
3 0.908 0.576 6 3.907 0.248
Mean ± SD 2.83 ± 3.55 0.50 ± 0.35 Mean ± SD 6.92 ± 5.67 6.92 ± 0.10
 
 
Figure 9: 1/T1 MR Brain Image Colormaps. Colormaps generated from MR data representing the inverse 
relaxivities.  The red denotes the areas where gadolinium accumulated.  Top row shows animals treated 
with plain liposomes (left to right: ID# 4-6).  Bottom row shows animals treated with imipramine blue 
liposomes (left to right: ID# 1-3). Scale bar = 1cm. 
 
5. DISCUSSION 
MMP-2 and MMP-9 activity was not significantly affected by varying concentrations 
of Imipramine Blue.  Although U87 and RT2A cells treated with 50 μM IB were 
significantly different from other treatment groups, it is expected that the significant 
decrease observed is due to cell death.  From previous in vitro cytotoxicity assays, 40 μM 





prediction that Imipramine Blue affects basement membrane degradation, the first stage 
of angiogenesis.  For future studies, it is suggested that positive control group be added, 
such as emodin, an MMP-2 and MMP-9 inhibitor observed in glioma cells.22  The 
addition of a positive control group will confirm the appropriate sensitivity of the assay if 
no fluorescence is emitted.  Zymography could also be performed for more quantitative 
results.  Also, it is advised to look at other MMPs that could be involved in matrix 
degradation that are less commonly implicated in glioma since they still may be involved. 
The HUVEC invasion assay showed a decreasing trend in endothelial cell migration 
when cells are treated with Imipramine Blue, but the results are not significant.  
Increasing the sample size by adding experiments for each treatment will provide more 
results.  The assay performed only assesses the effect of IB on treated endothelial cells.  
Future experiments can simulate the effect of IB-treated glioma cells and their ability to 
recruit endothelial cells.  This would involve glioma cells plated in a 24 well plate.  Once 
adhered, cells would be treated with either 0 μM IB or 5 μM IB in basal media.  Cells 
would be treated for 3 hours.  In vitro, the effects of IB have been observed as early as 3 
hours after treatment.  After 3 hours of treatment, media will be replaced with low serum 
HUVEC media.  Transwells containing seeded, untreated HUVECs using the method 
mentioned previously, will then be   placed in the glioma-coated 24-well plate and 
incubated for 24 hours.  Invasion through the membrane will be quantified using the 
same method previously mentioned.  The addition of the coated glioma cell lines will 





No conclusions were made on the effect of Imipramine Blue on tube formation.  
Future experiments should include tube formation assays involving HUVECs treated 
with: varying concentrations of IB and a positive control tube formation inhibitor such as 
Avastin.1  This will assess Imipramine Blue’s possible abilities to prevent endothelial cell 
tube formation. The tube formation assay was not conducted with IB, but the Cultrex 
protocol was optimized with the use of low serum HUVEC media and 4% 
paraformaldehyde fixation to ensure proper tube formation prior to and after fixation. 
In addition to no significant changes in MMP activity and HUVEC migration, no 
significant differences were observed between treatment groups in terms of endothelial 
transfer coefficients and cross-sectional tumor area, suggesting that IB does not affect 
vascular permeability.  These results reject the alternative hypothesis that Imipramine 
Blue has an anti-angiogenic effect.  In vivo, rats inoculated with the 3RT1-RT2A model 
were treated with saline or liposomal IB. Brains were dissected, sectioned, and stained for 
RECA-1 (rat endothelial cell antibody 1, a marker for blood vessels).  RECA-1 staining 
showed that there were no significant differences in blood vessel amounts and cross-
sectional areas between rats treated with plain liposomes and rats treated with IB 








Figure 10: Effects of Imipramine Blue on Blood Vessels of Rat Gliomas (3RT1-RT2A).  Rats were 
inoculated with gliomas and treated with either liposomal IB or saline.  Brains were cryosectioned, stained 
for RECA-1, endothelial cell marker, and imaged along the border of the tumor.  Rats treated with saline 
(A) appeared to have the same amount of blood vessels as rats treated with liposomal IB (B).  Additionally, 
cross sectional areas of blood vessels did not vary between treatment groups.   (Scale bar 50 microns) 
 
The MRI method of determining vascular permeability is both novel and favorable 
because vascular permeability can be determined before perfusions, and the remaining 
dissected brain can be sectioned for histological analysis.  Other methods for determining 
vascular permeability include Evans Blue quantification.  This involves a tail vein 
injection prior to perfusions.  After perfusions, the brain is dissected and the Evans Blue 





pilot study, but no Evans Blue was extracted due to homogenizer problems.  Therefore, 
determining vascular permeability from MR images is highly favored because it avoids 
extraction errors without the need of processing the brain after perfusions.  Additionally, 
the use of dual-gadolinium liposomes increases circulation time allowing for a longer 
time frame for acquiring MR images but also decreases the necessary time for image 
acquisition due to the gadolinium’s contrast agent properties. 
 
A similar study was conducted comparing the effects of an anti-VEGF therapy on 
endothelial transfer coefficients in U87 inoculated tumors (400,000 cells in matrigel-
media suspension per animal).  Tumors were MR imaged on day 16.  Given the cell 
amount inoculated and the additional amount of time to MR image, tumor sizes from the 
U87 study were larger.  KPS values were ten times greater in U87 PBS-treated tumors 
(control 28.6 ±8.6 mL min-1cc-1 of tissue, mean ±SD) compared to the 3RT1-RT2A plain 
liposome-treated tumors (control 2.83 ± 3.55 mL min-1cc-1 of tissue, mean ±SD), but this 
is most likely due to the difference in treatment timelines.   Tumor size varied greatly 
within treatment groups, but this is probably due to the natural tumor size variability 
which depends on the individual animal.  Increasing the sample size will likely lower the 
variability within tumor groups.   
Many assumptions were made for this study, limiting the results.  Fractional plasma 
volume constants were taken from the control animals in the study by  Daldrup et al.  The 
study’s treatment groups had significantly different fractional plasma volume constants.  
If the treated Imipramine Blue animals did have a difference in vascular permeability, 
then estimating the fractional plasma volume to be the same could have eliminated a 





groups. For future experiments, a better method for determining fractional plasma 
volume should be implemented.  Additionally, a dual-gadolinium liposome 
pharmacokinetic study should be conducted to obtain a model for plasma gadolinium 
accumulation. 
 Despite the need for additional experiments, this method is still favorable for 
determining vascular permeability, and the addition of dual-gadolinium liposomes allows 
for longer circulation of contrast agent for longer image acquisition times and greater 
quality images.  KPS values were successfully determined from the MR images.  
Furthermore, this method allows for time point flexibility and post-perfusion analysis 
with the dissected brain.   
 
6. CONCLUSION 
MMP-2 and MMP-9 activity was not significantly affected by varying treatments of 
Imipramine Blue (within the viable concentrations).  HUVECs treated with IB were not 
significantly affected.  No conclusions were made in terms of tube formation, which 
should be investigated in future experiments.  The newly developed method for 
determining vascular permeability in vivo is favorable and should be used for future 
studies because permeability data can be extracted prior to perfusion, and after perfusion, 
the extracted brain can be used for more analysis.  Endothelial transfer coefficients were 
not significantly different between treatment groups.  The lack of significant changes in 
MMP activity, endothelial cell recruitment, and endothelial transfer coefficients suggest 
Imipramine Blue has no anti-angiogenic effects, rejecting the alternative hypothesis that 
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Table 1: Treatment Groups for Vascular Permeability Study 
Day Treatment 
0 Inoculate tumor  
4 Tail vein injections 
Group 1, liposomal IB (n=3) 
Group 2, plain liposomes (n = 3) 
7 Pre contrast images for random members of groups 1 and 2 
Tail vein injections of dual gadolinium liposomes, both groups 
10 MRI both groups 
12 Perfusions 
 
Table 2: Endothelial Transfer Coefficients (KPS) and Cross-Sectional Tumor Areas in Plain 
Liposome-Treated and Imipramine Blue Liposome-Treated 3RT1-RT2A Tumors. Units for KPS and 
cross sectional tumor area are mL min-1100 cc-1 of tissue and mm2.  No significant differences were 
observed between treatment groups in terms of endothelial transfer coefficients and cross-sectional tumor 
area (p1=0.3488, p2=0.187). 
Plain Liposomes  Imipramine Blue Liposomes 
ID # KPS 
Cross-
sectional 




1 0.647 0.808 4 13.466 0.058 
2 6.927 0.126 5 3.398 0.209 
3 0.908 0.576 6 3.907 0.248 










Figure 4: Nanoparticles delivered to tumor tissue via EPR Effect.  The endothelial cells lining the blood 
vessel are more spaced out allowing nanoparticles of up to 400 nm in diameter to pass through and 
accumulate in a tumor.6 
 
 
Figure 5: Effects of Imipramine Blue in Rat Glioma (3RT1-RT2A) Model.   Tumors were injected 
2mm anterior and lateral to lambda and 3 mm below the dura.  Animals were administered tail-vein 
injections (saline or liposomal IB) on Day 4 and 7 (after tumor inoculation) and perfused on Day 11.  
Brains were sectioned coronally and stained with DAPI to highlight nuclei.  The treated tumor appears 













































Figure 5: Predicted gadolinium concentration in plasma of rats treated with dual-gadolinium 





































B.  0 μM 
 
































Figure 6: MMP Activity in IB-Treated U87 Cells.  U87 cells were seeded on a basement membrane 
extract which included a dye-quenched collagen IV.  When the collagen IV is cleaved by MMP-2 and 
MMP-9, a green fluoroscein is emitted.  A. shows the treated U87 MMP-2 and MMP-9 activities.  
Asterixes denote the significant differences according to a one-way ANOVA and Tukey-post test (α=0.05).  
Significant differences were observed between treatment groups 0.001 μM IB and 50 μM IB (* p = 0.000),. 








B. 0 μM  
 































Figure 7:  MMP Activity in IB-Treated RT2A cells.  RT2A cells were seeded on a basement membrane 
extract which included a dye-quenched collagen IV.  When the collagen IV is cleaved by MMP-2 and 
MMP-9, a green fluoroscein is emitted.  A. shows the treated RT2A MMP-2 and MMP-9 activities.  
Asterixes denote significant differences according to a one-way ANOVA and Tukey-post test (α=0.05).  
Significant differences were observed between treatment groups 1 μM IB and 50 μM IB (* p = 0.016). B. 






Figure 8: Invasion of IB-Treated HUVECs.  HUVECs were seeded and treated  either 0 μM IB or 5 μM 
IB (n=3 per treatment), incubated for 24 hours, 4% paraformaldehyde fixed, DAPI stained, and imaged.  
Invasion through the transwell was quantified and normalized to the control.  Treated HUVEC invasion 





























Figure 9: 1/T1 MR Brain Image Colormaps. Colormaps generated from MR data representing the inverse 
relaxivities.  The red denotes the areas where gadolinium accumulated.  Top row shows animals treated 
with plain liposomes (left to right: ID# 4-6).  Bottom row shows animals treated with imipramine blue 








Figure 10: Effects of Imipramine Blue on Blood Vessels of Rat Gliomas (3RT1-RT2A).  Rats were 
inoculated with gliomas and treated with either liposomal IB or saline.  Brains were cryosectioned, stained 
for RECA-1, endothelial cell marker, and imaged along the border of the tumor.  Rats treated with saline 
(A) appeared to have the same amount of blood vessels as rats treated with liposomal IB (B).  Additionally, 
cross sectional areas of blood vessels did not vary between treatment groups.   (Scale bar 50 microns) 
 
 
 
